clinical trial · NCT05338502
Study of H2 Antagonist and a Proton Pump Inhibitor of Selpercatinib in Healthy Participants
Eli Lilly and Company·phase1·completed·n = 20
HealthySelpercatinibRanitidineOmeprazole
brief summary
The main purpose of this study is to learn about how H2 antagonist (ranitidine) and proton pump inhibitor (PPI) (omeprazole) affect Selpercatinib in healthy participants. Information about safety and tolerability will be collected. The study will last up to about 9 weeks, inclusive of screening period.
started
Jul 8, 2019
primary completion
Sep 3, 2019
completion
Sep 3, 2019
last updated
Oct 30, 2024
official title
An Open-Label, 3-Period, Fixed Sequence Study to Evaluate the Effect of an H2 Antagonist and a Proton Pump Inhibitor on the Single Dose Pharmacokinetics of LOXO-292 in Healthy Adult Subjects
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol